ADA26: AstraZeneca unveils positive data for Phase III-ready oral GLP-1RA

If the Phase III trials of the oral GLP-1RA are successful, AstraZeneca is set to join a fast-growing market. If the Phase III trials of the oral GLP-1RA are successful, AstraZeneca is set to join a fast-growing market. AstraZeneca said it will be advancing the oral GLP-1RA to Phase III trials. Credit: Mats Wiklund / Shutterstock.com AstraZeneca has unveiled data from two Phase IIb trials of its in-licensed oral glucagon-like peptide-1 receptor agonist (GLP-1RA), touting a 10.5% weight loss in patients. Data from the VISTA and SOLSTICE trials of elecoglipron, which was licensed from Eccogene in 2023, were unveiled at…

Source: Clinical Trials Arena